Stockreport

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Werewolf Therapeutics, Inc.  (HOWL) 
PDF – Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential regi [Read more]